13 Papers
9 Citations
Qin Lu is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy.
Qin Lu,Rui Chen,Shiyu Du,Chao Chen,Yongchun Pan,Xiaowei Luan,Jingjing Yang,Fei Zeng,Bangshun He,Xin Han,Yujun Song +10 more
TL;DR: In this paper , a nanoplatform (HMnMPH) was used for dual activation of cGAS-STING pathway in combination with CRISPR-Cas9 gene editing to silence programmed death ligand 1 (PD-L1) to trigger long-term immunotherapy.
44
Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway
TL;DR: Wang et al. as discussed by the authors showed that the two isomers of R-SFN and S-SNF significantly inhibited TGF-β1-induced migration and invasion in breast cancer cells.
DNAzyme-Assisted Nano-Herb Delivery System for Multiple Tumor Immune Activation.
Shiyu Du,Chao Chen,Suchen Qu,Hongxiu Song,Jingjing Yang,Yayao Li,Kunguo Liu,Qin Lu,Wenxin Luo,Run-Tian Wang,Xiaoxiang Guan,Yujun Song,Xin Han +12 more
TL;DR: This study provides a general strategy for targeted gene inhibition and GA release, which is valuable for the development of potential tumor immunotherapies.
22
Turning Hot into Cold: Immune Microenvironment Reshaping for Atherosclerosis Attenuation Based on pH-Responsive shSiglec-1 Delivery System.
TL;DR: A pH-responsive and charge-reversible nanosystem, referred to as Au-PEI/shSiglec-1/PEI-acetylsalicylic acid (ASPA NPs), efficiently reshaped AIM by inhibiting immune cell infiltration, lipid antigen presentation, and pro-inflammation provided a feasible therapeutic strategy for atherosclerosis immunotherapy.
13
Remodeling of the liver fibrosis microenvironment based on nilotinib-loaded multicatalytic nanozymes with boosted antifibrogenic activity
Huaqing Jing,Yingzi Ren,Yue Zhou,Min Xu,Sona Krizkova,Zbynek Heger,Qin Lu,Siyu Wang,Xiaoyang Liang,Vojtech Adam,Nan Li +10 more
TL;DR: Researchers developed nilotinib-loaded nanozymes that inhibit hepatic stellate cell activation, eliminate reactive oxygen species, and alleviate hypoxia, thereby remodeling the liver fibrosis microenvironment with boosted antifibrogenic activity and reduced toxicity.
12